Release date: 2008-05-14 Biochip: Opening a Window for Tumor Research——Interview with Zhan Qimin, Associate Dean of the Chinese Academy of Medical Sciences
GENREAL NAME:
Amprolium 20% water soluble powder
For Veterinary Use Only
COMPOSITION:
Active ingredients: Each 1g contains Amprolium Hydrochloride 200mg.
Excipents: Anhydrous glucose
DESCRIPTION
A white or almost white powder.
PHARMACOLOGICAL ACTIONS:
Amprolium have a role in variety of chicken coccidiosis, in which to Eimeria tenella and E.acervulina the role of the strongest type of reactor, for E. necatrix, E.brunetti, E. maxima and E.Nitis the role is weaker. Amprolium play a major role in the first- generation of propagules coccidia, prevent the formation of merozoites, the role of the peak in the first three days after infection. In addition, some inhibitory effect on sexual reproductive stage fg sporozoites. It can be used for prevention and treatment of coccidiosis. This drug is a vitamin B1 or thiamine structural analogue,
TARGET SPECIES
Chicken, lambs and calves.
INDICATION
Amprolium Powder is intended for the prevention and treatment of coccidiosis in chicken and cattle
ADMINISTRATION AND DOSAGE
Usually administered as mixed water or mixed feed.
Chicken: 240mg amprolium hydrochloride per 1 liter drinking water for 5-7 days.
Lambs: 50-100mg amprolium hydrochloride/kg bodyweight daily for 4 days. By mixed feed.
Calves: 25-50mg amprolium hydrochloride/kg bodyweight, 1-2 times daily, for 5 days. By mixed feed or oral irrigation.
Disable the laying period.
CONTRAINDICATION
Do not administer to debilitated animals.
USE DURING PREGNANCY, LACTATION OR LAY
Suitable for use in pregnant and lactating animals.
Disable the laying period.
ADVERSE REACTION (FREQUENCY)
Toxicity is observed only at high doses. CNS signs are caused by thiamine deficiency, which may be reversed by adding thiamine to the diet.
CLINICALLY SIGNIFICANT DRUG INTERACTIONS
None.
SYMPTOMS AND TRENTMENT OF OVERDOSAGE
To treat amprolium overdose, thiamine should be administered parenterally or orally.
WITHDRAWAL PERIOD
For meat consumption: 7 days before slaughter.
STORAGE
Store in a tightly sealed container, protected from light, and at room temperature.
SHELF LIFE
3 years.
PACK SIZE
100g
DESCRIPTION OF PRODUCT AND PACKAGE
A white or almost white powder sealed with Aluminum foil bag, packaged in cartons.
NAME AND ADDRESS OF MANUFACTUER
Name: Hebei Kexing Pharmaceutical Co., Ltd.
Address: No.114 Changsheng Street, Luquan Development Zone, Shijiazhuang City, Hebei, China
Amprolium Hcl Powder,Amprolium Powder,Poultry Medicine Amprolium Powder,Amprolium Hcl Powder For Animal Hebei Kexing Pharmaceutical Co., Ltd. , https://www.kexingpharma.com
Due to the complex mechanism of occurrence and development, and the difficulty of treatment, major diseases such as tumors are still a hot spot for researchers in various countries. At present, China's cancer prevention and treatment strategy is the focus of advancement, and it is expected to move from the current status of the treatment to the early diagnosis to achieve better efficacy and less economic costs.
Biochip is a high-tech developed rapidly in the field of life sciences in the late 1980s. It mainly refers to the construction of micro biochemical analysis systems on the surface of solid chips through micromachining technology and microelectronics technology to achieve Accurate, fast, and high-throughput detection of proteins, DNA, and other biological components is hundreds of times more efficient than traditional methods of detection.
Is it possible to solve the problem by using various types of biochips according to the problems in biomedical and clinical oncology research? We participated in the "Application Conference of Biochips in Medical and Food Security" (co-organized by the Ministry of Science and Technology, AQSIQ, Tsinghua University, China Pharmaceutical Biotechnology Association and Boao Biotechnology Co., Ltd.), and we interviewed the Chinese Academy of Medical Sciences. Associate Dean, Vice President of Peking Union Medical College, and Director of the State Key Laboratory of Molecular Oncology, Zhan Qimin.
Biochips are expected to become routine testing projects
Zhan Qimin was exposed to biochip technology when he was working in the United States. Talking about the application prospect of this technology in cancer research, he believes: "From the frontier of international research, everyone has higher expectations for using biochips to study tumors." Currently, the most used in the laboratory is the expression spectrum chip. MicroRNA chips and SNP chips, as well as transcription chiplets, cell chips and tissue chips, have become indispensable tools for cancer research. Zhan Qimin believes that the current research direction that enables biochips to produce practical applications faster is to screen out a small number of related genes using whole-genome expression profiling chips, and to make application-type small chips for clinical diagnosis or auxiliary diagnosis - which may become A routine testing program at the hospital.
Zhan Qimin believes that the key to the industrialization of this cutting-edge technology of biochips is the effective interface with clinical practice. As the leader of the national "863" program in the field of biological and medical technology, and the chief scientist of the "973" national major research project (tumor metastasis), he considered not only static research, but also how to establish a frontier. The transformation mechanism of technological achievements has enabled the people to truly enjoy the benefits brought by the country's continuous investment in basic and applied research over the years. "Engineering and technical personnel engaged in the research and development of biochips should have more contact and interaction with clinical experts, so that doctors can use them as soon as possible: first, clinical questions are raised by clinicians, and then controversial by scientific research personnel into scientific problems, and finally converted by chip experts. For technical problems, speed up the development process. For example, if the clinical sample size is small, the sensitivity of the biochip is a key. Only by solving this problem can some of the clinicians meet the needs." Zhan Qimin said that he is now working. Part of it is the joint government related functional institutions, universities, research institutes and biotechnology companies to build a docking platform to jointly promote the industrialization of cutting-edge biomedical technologies including biochip technology, and strive to create as large a Social benefits.
"Individualization" becomes the current research trend
Due to unclear etiology, complicated pathogenesis, and variable clinical manifestations, many cancer patients often have significant individual differences in treatment outcomes. A drug may only be effective for a patient population with a specific genetic variation, but not for other patient populations. How to use individual differences to explore individualized treatment has become the current research trend.
Zhan Qimin cited the example of breast cancer to illustrate the importance and urgency of individualized treatment of cancer. "Chemotherapy and endocrine therapy are currently the main means of treating breast cancer, which can reduce the risk of recurrence and metastasis in about 1/3 of patients, but another 70% of patients who receive these adjuvant treatments cannot benefit because they do not treat chemotherapy and endocrine therapy. Sensitive, resulting in over-treatment, not only low efficacy, increased patient suffering, but also increased the economic burden of the family and the country." Zhan Qimin believes that it is necessary to explore the predictive factors of breast cancer treatment, from many factors affecting efficacy Factors related to treatment sensitivity. "For example, differentiate patients who are sensitive and insensitive to chemotherapy by gene expression profiling chips, and carry out targeted treatments; at the same time, find the best treatment drugs and programs to improve the efficacy."
At the end of the interview, we asked Zhan Qimin to predict the progress of the implementation of cancer prevention and treatment in China. "China is a country with high incidence of cancer, with a large population, high morbidity and mortality. The government attaches great importance to this. In the principle of building a harmonious society and people-oriented, China has included the prevention and early diagnosis of cancer in the middle and long term of the country. In the Science and Technology Development Plan, we invested a lot of financial and material resources, focused on the 'external introduction of talents', trained excellent research teams, built the National Chip Research Center, the Genomics Research Center, the Proteome Center, and the Bioinformatics Center. And other relevant research platforms, and use the domestic rich sample database resources to actively cooperate with international high-level cancer research institutions. In the next 5 to 10 years, China is expected to achieve leapfrog development in cancer research and clinical applications. Zhan Qimin is full of confidence.
- National Food and Drug Administration website